Entecavir (Baraclude)
Small molecule
Evidence outlook
Approved: Chronic Hepatitis B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: NCT00035789 · Phase 3 · met primary endpoint · grade pending
Also approved (1)
- Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis; decompensated liver disease. For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00035633 NCT00035633 · Chronic Hepatitis B Registry: NCT00035633 | 3 | — 2005-02 | Primary endpoint (histologic improvement at week 48): 72% entecavir vs 62% lamivudine, P=0.009. | not yet graded | link ↗ |
View 1 more trial
NCT00035789 NCT00035789 · Chronic Hepatitis B Registry: NCT00035789 | 3 | — 2005-05 | Primary endpoint (histologic improvement at week 48): 70% entecavir vs 61% lamivudine, P=0.01. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (24)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (68)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (34)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (27)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other HBV polymerase (reverse transcriptase) drugs
lamivudine (Epivir-HBV), tenofovir alafenamide (Vemlidy), Besifovir dipivoxil (Besivo), Tenofovir amibufenamide (Hengmu), Entecavir (Cavir). Compare all 6 HBV polymerase (reverse transcriptase) drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Hepatitis B: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Entecavir (Baraclude): this drug | Approved | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Protein / enzyme therapeutic | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Interferon Alfa-2b (Intron A) | Approved | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lamivudine (Epivir-HBV) | ApprovedUS marketing discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | HBV polymerase (reverse transcriptase) | Reliable signal | Featured results are non-efficacy only in this race | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Reliable signal | NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants | |
| Besifovir Dipivoxil (Besivo) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | Partial signal | NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019). | |
| Hepatitis B Immune Globulin (I.V.-Hepabig) | Phase 3 | Polyclonal Antibody (human Hepatitis B Immunoglobulin) | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3605 | Phase 3 | — | HBV core protein | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-008 | Phase 3 | Vaccine | Hepatitis B virus antigens (HBsAg + HBcAg) | not yet graded | No reviewed efficacy summary in this indication | |
| AHB-171 | Phase 2 | RNA / oligonucleotide | HBV RNA | not yet graded | No reviewed efficacy summary in this indication | |
| Daplusiran / Tomligisiran | Phase 2 | RNA / oligonucleotide | HBV RNA (X and S transcripts) | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Hepalatide | Phase 2 | Peptide | NTCP | not yet graded | No reviewed efficacy summary in this indication | |
| Libevitug (HH-003) | Phase 2 | Monoclonal antibody | HBV/HDV large envelope protein (PreS1 domain) | not yet graded | No reviewed efficacy summary in this indication | |
| Metacavir | Phase 2 | Small molecule | HBV reverse transcriptase (nucleoside analog) | not yet graded | No reviewed efficacy summary in this indication | |
| REP 2139-Mg | Phase 2 | — | HBsAg release (nucleic acid polymer) | not yet graded | No reviewed efficacy summary in this indication | |
| T101 | Phase 2 | Biologic (subtype unspecified) | HBV core, polymerase and envelope antigens | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3810 | Phase 2 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| CRMA-1001 | Phase 1/2 | Gene therapy / editing | HBV genome (cccDNA and integrated DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Hepadvax | Phase 1/2 | Vaccine | HBsAg (PreS) immunization | not yet graded | No reviewed efficacy summary in this indication | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LW231 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| PA1010 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| TQA3038 | Phase 1/2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ACT201 | Phase 1 | RNA / oligonucleotide | HBsAg | not yet graded | No reviewed efficacy summary in this indication | |
| CB06-036 | Phase 1 | — | TLR8 | not yet graded | No reviewed efficacy summary in this indication | |
| DA-2803 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Entecavir (Cavir) | Phase 1(overall) | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| HECN30227 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| SA1211 | Phase 1 | RNA / oligonucleotide | Hepatitis B virus RNA (dual-target siRNA) | not yet graded | No reviewed efficacy summary in this indication | |
| TVAX-028 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Adefovir Dipivoxil (Hepsera) | Discontinued | Small molecule | HBV polymerase (reverse transcriptase) | not yet graded | No reviewed efficacy summary in this indication | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Telbivudine (Tyzeka) | Discontinued | — | HBV polymerase (reverse transcriptase) | Partial signal | NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Entecavir (Baraclude) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.